Matches 1 - 50 out of 66 1 2 >


Match Document Document Title
DE102016125645A1 D-enantiomeric peptides for the treatment of chronic and neuropathic pain  
The present invention relates to a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologues having at least 50% identity and...
DE102013012432A1 Immunotherapy of Prostate Cancer  
The present invention relates to a pharmaceutical composition for immunotherapy of prostate cancer, the use of peptides for the immunotherapy of prostate cancer as well as a usable in the context...
DE102011118029A1 Modified antibiotic peptides with variable systemic release  
This invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and Oncocins, preferably with increased stability, reduced immune response and improved...
DE10344561B4 Using a tetra, penta and octapeptide of royal jelly  
Use of the tetrapeptide NEVN, the pentapeptide NEVNF and the octapeptide NEVN NEVN to achieve antimicrobial effects in human and veterinary medicine.
DE10392821B4 Synteseverfahren for alanylglutamine  
A process for producing alanylglutamine, comprising the steps: 1) preparing an activated alanine ester obtained by reacting 1 mol of N-terminally protected alanine with 1 to 3 moles of...
DE102009034779A1 Synthetic analogues of bacterial lipopeptides and their use for the therapy and prophylaxis of allergic diseases  
The present invention relates to novel, of a spore germination protein of the species Bacillus cereus-derived Lipopepitide with immunostimulatory activity, processes for the preparation of...
DE102008037564A1 Composition for the production of anti-amyloid beta-peptide antibodies with D-peptides  
The present invention relates to a composition comprising D-peptides or antibodies, for use as a therapeutic agent and / or prevent diseases whereina) interact D-peptides with an amyloid...
DE20122915U1 Peptidomimetics as protease inhibitors  
Compound of the formula 1 in which: - R0 a bond or difluoromethylene and - R1 Hydrogen, an optionally substituted aliphatic group, an optionally substituted cyclic group or an optionally...
DE4042752B4 Process for the preparation of microparticles containing an active agent in a biodegradable polymeric carrier,  
process for the preparation of microparticles comprising an agent in a biodegradable, biocompatible polymeric carrier included with a) the polymeric carrier material in a suitable Solvent, in...
DE4021517B4 Formulations with delayed release of water-soluble peptides  
formulation with slowed release of octreotide or Nα- [Α-glucosyl- (1-4-deoxyfructosyl)] - or Nα- [Β-deoxyfructosyl] -DPhe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr-ol in free form, Salt form or in the form of...
DE102005054700B4 New dual peptidase inhibitors as prodrugs for the treatment of inflammatory and other diseases  
compounds of the general formulas (1) and (2) ABD-B'-A '(1) andABDE (2), wherein- A and A 'are identical or different could be and for the rest are, wherein X is S, O, CH2, CH2CH2, CH2O or CH2NH...
DE102007002386A1 Pharmaceutically active compounds  
The present invention relates to pharmaceutically active compounds from an isoflavone or isoflavone glycoside and covalently with this connected, an amino acid, a peptide or peptide derivative...
DE102006047529A1 Dermatological composition contains an oligopeptide as an agent for increasing skin sensitivity  
Dermatological composition contains an oligopeptide with a sequence of 4-6 amino acids, including the dipeptide sequence Ile-Pro or Pro-Ile, as an agent for increasing skin sensitivity. ACTIVITY :...
DE102005054700A1 New dual peptidase inhibitors as prodrugs for the treatment of inflammatory and other diseases  
The Invention relates to compounds of the general formulas (1) and (2)ABD-B'-A '(1) and ABDE (2), wherein- A and A 'are the same can be different or and for rest are, wherein X is S, O, CH2,...
DE4392401B4 Verfahren zur Herstellung einer Lösung oder Dispersion eines Peptid-Polyester-Salzes  
Verfahren zur Herstellung einer Lösung oder Dispersion eines Salzes, das aus einem Kation, das sich von einem Peptid mit wenigstens einer basischen Gruppe ableitet, und einem Anion, das sich von...
DE102006048362A1 Composition, useful to treat and/or protect disease condition e.g. circulatory disorder, comprises an active substance combination of isoflavone or isoflavone glycoside and a peptide derivative  
Pharmaceutical composition comprises an active substance combination of at least an isoflavone or isoflavone-glycoside and/or their salts or solvates and at least a peptide or its derivative with...
DE4342092B4 Long-acting injection suspension and process for producing  
Pharmaceutical Sustained-release composition containing a Embonatsalz an LHRH analogs, wherein the Particle diameter of the salt particles predominantly between 80 and 125 .mu.m and it is, in...
DE60118395T2 Pharmaceutical Compositions SUSTAINED RELEASE FOR PARENTERAL APPLICATION OF HYDROPHILIC SUBSTANCES  
Stable, biologically compatible pharmaceutical compositions in the form of water-in-oil microemulsions (w/o), for the sustained release by parenteral administration of active ingredients which are...
DE102005023761A1 At the Lck-SH3 and Hck SH3 domain-binding peptides  
The Invention relates to the Lck-SH3 and Hck SH3 domain binding Peptides.The proteins according to the sequences 1, 2 and 4 to bind the domain Lck-SH3 and Hck SH3 on, whereby effector molecules of...
DE60115222T2 COMBINING defibrotide AND G-CSF AND THEIR USE FOR ACTIVATION hematopoietic Progenitor Cells  
A description is given of a method of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the method is characterised by the administration...
DE102005002353A1 Use of receptor multimerization epitope (RME) of advanced glycation end product receptor (AGER) as immunogen, useful for preparing antibodies for diagnosis and treatment of e.g. spinal injuries or diabetic complications  
Use of the receptor multimerization epitope (RME) of the advanced glycation end product receptor (AGER) as an immunogen for preparing polyclonal antiserum or monoclonal antibodies against AGER-RME...
DE3991505B4 Somatostatin peptides, their analogues or derivatives, to processes for their preparation and pharmaceutical compositions containing them  
somatostatin and their analogs or derivatives having at least one chelating group for a carry detectable element, said chelating group with a terminal amino group of the peptide, either directly...
DE4007605B4 SDK peptides, process for their preparation and therapeutic compositions containing them  
peptides having the general formula H2N - W - Ser - Asp - Lys - X - OH wherein X is a Pro or Lys residue or a valence bond, and W represents a Thr or Pro residue, or a valence bond, with the...
DE102004030227A1 Treatment of diseases (e.g. proliferative diseases of tumor cells, ophthalmic diseases and skin diseases) associated with angiogenesis comprises administration of carbamide compounds  
Use of carbamide compounds (I) or their salts, solvates, hydrates or formulations, for the treatment of diseases associated with angiogenesis. Use of carbamide compounds of formula (I) or their...
DE102004026135A1 An MHC molecules binding tumor associated peptides  
The Invention relates to a tumor-associated peptide with an amino acid sequence the selected is selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 of the attached sequence...
DE10392821T5 Synteseverfahrens for alanylglutamine  
synthesis method for alanylglutamine, comprising the steps: 1) formation of an activated ester by the reaction of 10 mmol of N-terminally protected alanine, 10 ~ 30 mmol triphenylphosphine and 10...
DE10340260A1 Compositions and methods for treatment and prevention of TSE, and to processes for the preparation of the agent  
The Invention relates to a composition or a pharmaceutical agent and a method for treatment, prevention and diagnosis of TSE and a process for production of the agent or pharmaceutical Agent....
DE202004012807U1 Cosmetic and dermatological compositions with DNA repair enzymes and oligopeptides  
Cosmetic topical or dermatological composition containing at least a DNA repair enzyme and at least one oligopeptide containing a NC2-C24acyl comprise and / or may be esterified, in a suitable...
DE10240064A1 Use of chemokine receptor antagonist for treatment of cancer and inhibition of metastasis, functions as ligand for the CXCR4 receptor  
Use of a chemokine receptor antagonist (A), acting as ligand for the CXCR4 receptor, for apoptosis-inducing treatment and/or inhibiting metastasis of cancer cells that have affinity for stromal...
DE10157628A1 Solution for injection of an LHRH antagonist  
The aqueous injection solution comprising an LHRH antagonist contains in addition to the LHRH antagonist, such as cetrorelix, an organic, physiologically compatible acid and optionally a...
DE10154689A1 Substituted amino ketone compounds  
The present invention relates to compounds of the general formula (I): B-(CH--R<1>)n--C(=X<2>)-D and pharmaceutically acceptable salts thereof including steroisomers, to the use of the compounds...
DE10150203A1 Use of dipeptidyl peptidase IV inhibitor in treatment of cancer  
Treatment of cancer or related disorder involves the use of a composition prepared from at least one dipeptidyl peptidase IV (DPIV) or DPIV-like enzyme activity inhibitor. The inhibitor is...
DE10146737A1 Coniosulfides and their derivatives, process for their preparation and use as medicines  
The invention relates to compounds of formula (I), which are formed from the micro-organism Coniochaeta ellipsoidea Udagawa, DSM 13856, or from one of its mutations and/or variants during...
DE10137174A1 Method of modifying T-cell populations, e.g. for treatment of HIV infection or cancer, comprises administrating luteinizing hormone releasing hormone antagonist at controlled dose insufficient to cause chemical castration  
New method of modifying the T-cell population comprises the administration of peptide or non-peptide luteinizing hormone releasing hormone (LHRH) antagonists (I), at doses which reduce sexual...
DE10115668A1 Agent for treating stroke, blood flow disorders and accumulation of blood in tissues, comprises kinin B1 receptor stimulant, e.g. interleukin-1beta, des-(Arg-9)-bradykinin or captopril  
An agent for treating stroke comprises a kinin B1 receptor stimulant (I). An Independent claim is also included for the use of (I) in combating blood flow disorders and accumulation of blood in...
DE10106852A1 Anti-inflammatory compounds  
The invention relates to the use of a compound of formula Lys-X, wherein X represents a hydroxyl group, an amino group, alkoxy, pro or pro-thr, or to the use of a pharmaceutically acceptable salt...
DE10141749A1 Inhibiting or stimulating angiogenesis by modulating the kinin B1 receptor, useful e.g. for treating solid tumors, macular degeneration, diabetic retinopathy or cardiac infarction  
A composition (I) for controlling angiogenesis is by influencing the kinin B1 receptor is claimed.
DE10041423A1 biphenyl  
The invention relates to novel biphenyl derivatives of the general formula (I), wherein R<4> represents an aromatic heterocycle, and to the physiologically acceptable salts or solvates thereof....
DE19958121A1 Tyrosine and tryptophan-containing peptides as antioxidants  
The invention relates to the use of tryptophan-containing, especially tryptophan- and tyrosine-containing, peptides as antioxidants. The compounds can be used in therapy or as prophylaxis of...
DE19919148A1 Interleukin 12 derived peptide homodimers and peptide heterodimers  
The invention relates to homodimers or heterodimers of peptide monomers which have the amino acid sequence KHYSCTAEDID (monomer I), PPVGEADPYRVKMQ (monomer II), AALQNHNHQQIILDK (monomer III),...
DE19828113A1 Prodrugs of inhibitors of dipeptidyl peptidase IV  
The invention relates to prodrug compounds of inhibitors of dipeptidyl peptidase IV (DP IV). Said prodrug compounds comprise general formulas (A-B-C), whereby A represents an amino acid, B...
DE19815060A1 Pharmaceutical preparations for the therapy of side effects during and / or after a GnRHa therapy  
The invention relates to the use of at least one active agent from the following group: 17 alpha -estradiol, its chemically modified derivatives and chemically modified derivatives of 17 beta...
DE19733651A1 Aqueous aerosol formulations containing biologically active macromolecules and methods for producing corresponding aerosols  
The invention relates to aqueous aerosol preparations containing biologically active macromolecules for producing inhalable aerosols without propellant gases.
DE19729591A1 Agents for the treatment and / or prophylaxis of microcirculation disorders  
The present invention concerns the use of a ligand for fibrinogen and/or fibrin in order to produce an agent for the treatment and/or prophylaxis of microcirculation disorders and/or for...
DE3845000C2 Compsn. contg. somatostatin analogues for treating breast cancer  
Pharmaceutical compsns. contg. a somatostalin analogue (A) and lactic acid are new. The use of (A)= for treating breast cancer is also new. Pref. compsns. also contain (1) a basic cpd. to give pH...
DE19644994A1 Diagnostic agent  
The invention concerns a diagnostic agent for improving the effectiveness of hysteroscopy, characterized by a content of an LH-RH antagonist, in particular Cetrorelix. The agent is provided for...
DE19638044A1 Immunogenic peptides of foot-and-mouth disease virus  
This invention concerns FMDV-vaccines based on peptides with a sequence of at least eight amino acids which corresponds to a partial sequence from the unstructured protein area of FMDV which has...
DE19545257A1 A process for the production of morphologically uniform microcapsules and microcapsules prepared by this method  
The invention concerns a method of producing morphologically uniform microcapsules containing peptides, proteins or other water-soluble biologically active substances as active substance, and...
DE19544212A1 New LH-RH antagonists having improved activity  
New LH-RH antagonists are disclosed, in particular peptidomimetics and peptides modified in a side chain, their salts with pharmaceutically acceptable acids and a process for preparing these LH-RH...
DE4430601A1 Cell adhesion peptides to modify the adhesion behavior of eukaryotic cells with each other  
The invention concerns adherence peptides for use in modifying mutual adhesion among eukaryotic cells and the use of such peptides to promote or inhibit cell-to-cell adhesion among eukaryotic...

Matches 1 - 50 out of 66 1 2 >